NYSE:PFE - Pfizer News Headlines

Sign in or create an account to add this stock to your watchlist.
$42.40 +0.43 (+1.02 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$42.40
Today's Range$42.08 - $42.51
52-Week Range$34.32 - $46.47
Volume17.98 million shs
Average Volume26.36 million shs
Market Capitalization$252.40 billion
P/E Ratio14.13
Dividend Yield3.43%
Beta0.77

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
Here's The Dark Horse Contender That Could Break Up Bristol-CelgeneHere's The Dark Horse Contender That Could Break Up Bristol-Celgene
finance.yahoo.com - February 15 at 3:45 PM
Sarepta's NDA for DMD Drug Golodirsen Gets Priority ReviewSarepta's NDA for DMD Drug Golodirsen Gets Priority Review
finance.yahoo.com - February 15 at 10:47 AM
What Are the Key Growth Drivers for GlaxoSmithKline in 2019?What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
finance.yahoo.com - February 15 at 10:47 AM
Favorable News Coverage Somewhat Likely to Affect Pfizer (PFE) Stock PriceFavorable News Coverage Somewhat Likely to Affect Pfizer (PFE) Stock Price
www.americanbankingnews.com - February 15 at 5:31 AM
Pfizer Maintains Lead in ED MarketPfizer Maintains Lead in ED Market
www.baystreet.ca - February 14 at 11:48 AM
G-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.s Groton, Conn. SiteG-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.'s Groton, Conn. Site
www.bizjournals.com - February 14 at 11:48 AM
Pfizer still holds the lead in the erectile dysfunction market even as Viagra sales falterPfizer still holds the lead in the erectile dysfunction market even as Viagra sales falter
www.cnbc.com - February 14 at 6:50 AM
Pfizer Inc. (PFE) Short Interest UpdatePfizer Inc. (PFE) Short Interest Update
www.americanbankingnews.com - February 14 at 4:27 AM
Pfizer Inc. (PFE) Given Average Recommendation of "Hold" by AnalystsPfizer Inc. (PFE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 14 at 3:36 AM
Pfizer and Eli Lilly: How Dividends and Tax Rates Stack UpPfizer and Eli Lilly: How Dividends and Tax Rates Stack Up
finance.yahoo.com - February 13 at 10:34 AM
What Are the Key Growth Drivers for Pfizer in Fiscal 2019?What Are the Key Growth Drivers for Pfizer in Fiscal 2019?
finance.yahoo.com - February 13 at 10:34 AM
Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?
finance.yahoo.com - February 12 at 3:35 PM
What Analysts Recommend for Pfizer and Eli Lilly in FebruaryWhat Analysts Recommend for Pfizer and Eli Lilly in February
finance.yahoo.com - February 12 at 3:35 PM
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority ReviewPfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review
www.zacks.com - February 12 at 10:27 AM
Pfizer and Astellas Xtandi successful in late-stage prostate cancer studyPfizer and Astellas' Xtandi successful in late-stage prostate cancer study
seekingalpha.com - February 12 at 10:27 AM
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell CarcinomaFDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
finance.yahoo.com - February 12 at 10:27 AM
Merck, Pfizer combo treatment boosts kidney cancer survivalMerck, Pfizer combo treatment boosts kidney cancer survival
finance.yahoo.com - February 12 at 10:27 AM
Better Buy: Gilead Sciences vs. PfizerBetter Buy: Gilead Sciences vs. Pfizer
finance.yahoo.com - February 12 at 10:27 AM
Stock Market News For Feb 12, 2019Stock Market News For Feb 12, 2019
finance.yahoo.com - February 12 at 10:27 AM
Stocks making the biggest moves midday: Avis Budget Group, Pfizer, Tesla & moreStocks making the biggest moves midday: Avis Budget Group, Pfizer, Tesla & more
www.cnbc.com - February 11 at 12:49 PM
Pfizer (PFE) Given Coverage Optimism Score of 1.88Pfizer (PFE) Given Coverage Optimism Score of 1.88
www.americanbankingnews.com - February 9 at 5:22 AM
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's WhyThis Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
finance.yahoo.com - February 8 at 3:39 PM
Pfizer recalls contaminated high blood pressure drug in JapanPfizer recalls contaminated high blood pressure drug in Japan
seekingalpha.com - February 8 at 12:01 PM
Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from PfizerStrong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from Pfizer
feeds.benzinga.com - February 8 at 4:29 AM
Eli Lilly Stock Falls Because 2019 Isn’t 2018Eli Lilly Stock Falls Because 2019 Isn’t 2018
finance.yahoo.com - February 6 at 3:45 PM
Pfizer Biopharmaceuticals Groups Late-Stage Pipeline Looks Well PositionedPfizer Biopharmaceuticals Group's Late-Stage Pipeline Looks Well Positioned
seekingalpha.com - February 6 at 12:00 PM
Pfizer CEO Bourla plans to testify at Senate drug pricing hearingPfizer CEO Bourla plans to testify at Senate drug pricing hearing
finance.yahoo.com - February 6 at 12:00 PM
Cancer-Vaccine Maker BioNTech Considering an IPO in U.S.Cancer-Vaccine Maker BioNTech Considering an IPO in U.S.
finance.yahoo.com - February 5 at 3:51 PM
Pfizers (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod - NasdaqPfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod - Nasdaq
www.nasdaq.com - February 5 at 10:41 AM
Dow Movers: PFE, AAPLDow Movers: PFE, AAPL
www.nasdaq.com - February 4 at 3:35 PM
Pfizers (PFE) New Lung Cancer Drug Vizimpro Gets CHMP NodPfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod
www.zacks.com - February 4 at 8:23 AM
Pfizer's Next 3 Years: What Investors Can ExpectPfizer's Next 3 Years: What Investors Can Expect
finance.yahoo.com - February 3 at 11:00 AM
A War on High Drug Prices Could Boost BiosimilarsA War on High Drug Prices Could Boost Biosimilars
finance.yahoo.com - February 3 at 11:00 AM
Pfizers Next 3 Years: What Investors Can ExpectPfizer's Next 3 Years: What Investors Can Expect
www.fool.com - February 3 at 9:50 AM
Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations - Business WirePfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations - Business Wire
www.businesswire.com - February 2 at 3:35 PM
It's Official: Trump Proposes Plan to Stop Skyrocketing Drug PricesIt's Official: Trump Proposes Plan to Stop Skyrocketing Drug Prices
finance.yahoo.com - February 2 at 11:01 AM
Douglas M. Lankler Sells 5,000 Shares of Pfizer Inc. (PFE) StockDouglas M. Lankler Sells 5,000 Shares of Pfizer Inc. (PFE) Stock
www.americanbankingnews.com - February 1 at 8:30 PM
Pfizer Inc. (PFE) EVP Sells $1,598,172.00 in StockPfizer Inc. (PFE) EVP Sells $1,598,172.00 in Stock
www.americanbankingnews.com - February 1 at 8:28 PM
Pfizer Gets Positive CHMP Opinion For Vizimpro 45 MgPfizer Gets Positive CHMP Opinion For Vizimpro 45 Mg
www.nasdaq.com - February 1 at 3:43 PM
European advisory group backs Pfizers Vizimpro in lung cancerEuropean advisory group backs Pfizer's Vizimpro in lung cancer
seekingalpha.com - February 1 at 3:43 PM
Pharma Catches Another Case Of M&A FeverPharma Catches Another Case Of M&A Fever
finance.yahoo.com - February 1 at 3:43 PM
Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for January 31, 2019 - NasdaqPfizer, Inc. (PFE) Ex-Dividend Date Scheduled for January 31, 2019 - Nasdaq
www.nasdaq.com - February 1 at 11:56 AM
Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating MutationsPfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
finance.yahoo.com - February 1 at 11:56 AM
Pfizers Q4 Earnings And What Lies Ahead For The Company In 2019Pfizer's Q4 Earnings And What Lies Ahead For The Company In 2019
www.forbes.com - January 31 at 4:13 PM
Pfizer Stock’s ‘Dark Period’ Might Finally Be OverPfizer Stock’s ‘Dark Period’ Might Finally Be Over
finance.yahoo.com - January 31 at 3:46 PM
Pfizer: Ibrance and Xtandi Are Key Oncology AssetsPfizer: Ibrance and Xtandi Are Key Oncology Assets
finance.yahoo.com - January 31 at 3:46 PM
Merck's Pneumococcal Vaccine Gets Breakthrough Therapy StatusMerck's Pneumococcal Vaccine Gets Breakthrough Therapy Status
finance.yahoo.com - January 31 at 3:46 PM
Oncology Portfolio: Pfizer’s Key Growth Driver in Fiscal 2018Oncology Portfolio: Pfizer’s Key Growth Driver in Fiscal 2018
finance.yahoo.com - January 31 at 10:28 AM
Brokers Offer Predictions for Pfizer Inc.s FY2019 Earnings (PFE)Brokers Offer Predictions for Pfizer Inc.'s FY2019 Earnings (PFE)
www.americanbankingnews.com - January 31 at 8:46 AM
Credit Suisse Group Upgrades Pfizer (PFE) to "Outperform"Credit Suisse Group Upgrades Pfizer (PFE) to "Outperform"
www.americanbankingnews.com - January 31 at 7:51 AM
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel